Opinion
Video
Author(s):
The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.
A Surgeon’s Perspective: How to Optimize Outcomes With Neoadjuvant Chemo/IO in Lung Cancer
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases
Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC
Earlier Use of Acalabrutinib Associated With Improved Survival in CLL
CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL
Ponatinib Regimen Shows Long-term Efficacy in Acute Lymphoblastic Leukemia
Englumafusp alfa/Glofitamab Combo Shows Early Responses in R/R Aggressive non-Hodgkin Lymphoma